Vertex Pharmaceuticals Preferred Over Arcutis Biotherapeutics for 2026 Investment

Industry
โดย Motley Fool·Read original
Summary · why it matters

Vertex Pharmaceuticals is favored over Arcutis Biotherapeutics as the better pharmaceutical stock to buy in 2026, according to a Motley Fool analysis. Arcutis, which markets the Zoryve dermatology line, saw revenue double to $376.1 million in fiscal 2025 but remains unprofitable with a net loss of $16.1 million, while Vertex generated $12 billion in revenue and nearly $4 billion in net income. The analysis notes that Arcutis achieved positive cash flow in the first quarter of fiscal 2026, yet its main product faces demand fluctuations tied to consumer spending and seasonality. Vertex, dominant in cystic fibrosis treatments covering 95% of U.S. patients, is expanding into gene editing and pain management, with Wall Street projecting sales to exceed $13 billion this year. The conclusion points to Vertex's established profitability, expanding market, and reasonable forward price-to-earnings ratio as decisive factors.

Impact on stocks 9

Biotech & Genomic Medicine± Mixed · 7 stocks
Arcutis Biotherapeutics Inc
ARQT
▼ NegativeDemandrelevance

Arcutis is unfavorably compared to Vertex; its Zoryve product faces demand fluctuations tied to consumer spending and seasonality, and it remains unprofitable.

Vertex Pharmaceuticals Inc
VRTX
▲ PositiveCapitalrelevance

Vertex is favored for its established profitability, expanding market, and reasonable forward P/E ratio, with Wall Street projecting sales to exceed $13 billion.

Financials▲ · 1 stocks
Health Care▲ · 1 stocks
© 2026 MarketDXNews